Does the media favor INSM or REGN?

In the previous week, Regeneron Pharmaceuticals had 69 more articles in the media than Insmed. MarketBeat recorded 70 mentions for Regeneron Pharmaceuticals and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Regeneron Pharmaceuticals' score of 0.82 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 42 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has better earnings and valuation, INSM or ARGX?

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 45.29 -$1.28B -$4.11 N/A argenex $4.25B 15.31 $1.29B $26.04 39.93

Is INSM or ARGX more profitable?

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% argenex 32.19% 43.59% 36.66%

Does the media refer more to INSM or ARGX?

In the previous week, argenex had 41 more articles in the media than Insmed. MarketBeat recorded 42 mentions for argenex and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat argenex's score of 0.75 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive argenex 13 Very Positive mention(s) 9 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, INSM or NTRA?

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 45.29 -$1.28B -$4.11 N/A Natera $2.31B 20.75 -$208.16M -$1.36 N/A

Is INSM or NTRA more profitable?

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.38% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Natera -7.11% -11.38% -7.87%

Does the media prefer INSM or NTRA?

In the previous week, Natera had 31 more articles in the media than Insmed. MarketBeat recorded 32 mentions for Natera and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Natera's score of 1.28 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 26 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INSM or RVMD?

In the previous week, Revolution Medicines had 11 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Revolution Medicines and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Revolution Medicines' score of 1.31 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better earnings and valuation, INSM or BIIB?

Biogen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 45.29 -$1.28B -$4.11 N/A Biogen $10.03B 3.19 $1.29B $5.65 38.37

Is INSM or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Insmed's net margin of -76.94%. Biogen's return on equity of 11.18% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -76.94% -123.94% -44.30% Biogen 8.32% 11.18% 6.88%

Does the media refer more to INSM or BIIB?

In the previous week, Biogen had 26 more articles in the media than Insmed. MarketBeat recorded 27 mentions for Biogen and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Biogen's score of 1.33 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 21 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Insmed (INSM) Competitors

$125.77 +0.69 (+0.55%)

As of 08/21/2026 04:00 PM Eastern

Compare

INSM vs. REGN, ARGX, NTRA, RVMD, and BIIB

Should you buy Insmed stock or one of its competitors? Insmed's main competitors and comparable companies include Regeneron Pharmaceuticals (REGN), argenex (ARGX), Natera (NTRA), Revolution Medicines (RVMD), and Biogen (BIIB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Insmed compare to Regeneron Pharmaceuticals?

Insmed (NASDAQ:INSM) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Insmed has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 69 more articles in the media than Insmed. MarketBeat recorded 70 mentions for Regeneron Pharmaceuticals and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Regeneron Pharmaceuticals' score of 0.82 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	42 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Regeneron Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
Regeneron Pharmaceuticals	$14.34B	5.99	$4.50B	$40.46	20.61

Regeneron Pharmaceuticals has a net margin of 27.86% compared to Insmed's net margin of -76.94%. Regeneron Pharmaceuticals' return on equity of 13.47% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Insmed presently has a consensus target price of $205.52, indicating a potential upside of 63.41%. Regeneron Pharmaceuticals has a consensus target price of $801.70, indicating a potential downside of 3.88%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Regeneron Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.62

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Regeneron Pharmaceuticals beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Insmed compare to argenex?

Insmed (NASDAQ:INSM) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, argenex had 41 more articles in the media than Insmed. MarketBeat recorded 42 mentions for argenex and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat argenex's score of 0.75 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
argenex	13 Very Positive mention(s)	9 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed currently has a consensus target price of $205.52, suggesting a potential upside of 63.41%. argenex has a consensus target price of $1,118.28, suggesting a potential upside of 7.55%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

60.3% of argenex shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, argenex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Insmed's net margin of -76.94%. argenex's return on equity of 43.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
argenex	32.19%	43.59%	36.66%

argenex has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
argenex	$4.25B	15.31	$1.29B	$26.04	39.93

Summary

argenex beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Natera?

Insmed (NASDAQ:INSM) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Natera has a net margin of -7.11% compared to Insmed's net margin of -76.94%. Natera's return on equity of -11.38% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Natera	-7.11%	-11.38%	-7.87%

Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

99.9% of Natera shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Natera has higher revenue and earnings than Insmed. Natera is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
Natera	$2.31B	20.75	-$208.16M	-$1.36	N/A

Insmed presently has a consensus target price of $205.52, suggesting a potential upside of 63.41%. Natera has a consensus target price of $319.38, suggesting a potential downside of 3.81%. Given Insmed's stronger consensus rating and higher possible upside, equities analysts clearly believe Insmed is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

In the previous week, Natera had 31 more articles in the media than Insmed. MarketBeat recorded 32 mentions for Natera and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Natera's score of 1.28 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	26 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Natera beats Insmed on 10 of the 16 factors compared between the two stocks.

How does Insmed compare to Revolution Medicines?

Insmed (NASDAQ:INSM) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

94.3% of Revolution Medicines shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Revolution Medicines has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Revolution Medicines' return on equity of -88.20% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Revolution Medicines	N/A	-88.20%	-57.85%

Revolution Medicines has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
Revolution Medicines	$11.58M	3,877.00	-$1.13B	-$8.82	N/A

In the previous week, Revolution Medicines had 11 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Revolution Medicines and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Revolution Medicines' score of 1.31 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Insmed has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Insmed currently has a consensus target price of $205.52, indicating a potential upside of 63.41%. Revolution Medicines has a consensus target price of $167.89, indicating a potential downside of 19.85%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Revolution Medicines beats Insmed on 9 of the 17 factors compared between the two stocks.

How does Insmed compare to Biogen?

Insmed (NASDAQ:INSM) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Biogen has a net margin of 8.32% compared to Insmed's net margin of -76.94%. Biogen's return on equity of 11.18% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Biogen	8.32%	11.18%	6.88%

Insmed currently has a consensus target price of $205.52, suggesting a potential upside of 63.41%. Biogen has a consensus target price of $227.07, suggesting a potential upside of 4.75%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Biogen had 26 more articles in the media than Insmed. MarketBeat recorded 27 mentions for Biogen and 1 mentions for Insmed. Insmed's average media sentiment score of 1.44 beat Biogen's score of 1.33 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	21 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Biogen has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	45.29	-$1.28B	-$4.11	N/A
Biogen	$10.03B	3.19	$1.29B	$5.65	38.37

Insmed has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market.

Summary

Biogen beats Insmed on 9 of the 17 factors compared between the two stocks.

Get Insmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INSM vs. The Competition

Export

Metric	Insmed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.47B	$4.01B	$7.38B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-30.60	11.62	272.60	24.25
Price / Sales	45.29	1,334.43	623.26	100.86
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	36.24	16.80	13.05	6.20
Net Income	-$1.28B	-$12.50M	$3.47B	$348.59M
7 Day Performance	1.64%	3.29%	2.09%	0.08%
1 Month Performance	17.09%	8.23%	6.63%	3.88%
1 Year Performance	-4.63%	55.05%	25.01%	16.98%

Insmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INSM Insmed	3.4421 of 5 stars	$125.77 +0.6%	$205.52 +63.4%	-4.6%	$27.47B	$606.42M	N/A	1,664	Positive News
REGN Regeneron Pharmaceuticals	4.0786 of 5 stars	$805.93 +0.3%	$801.70 -0.5%	+41.5%	$82.72B	$14.34B	19.92	15,410	Trending News Ex-Dividend
ARGX argenex	4.2626 of 5 stars	$987.84 +16.0%	$1,072.72 +8.6%	+57.5%	$53.26B	$4.25B	37.94	1,863	Trending News Analyst Forecast Analyst Revision High Trading Volume
NTRA Natera	2.7813 of 5 stars	$314.18 +1.4%	$319.38 +1.7%	+100.5%	$44.67B	$2.31B	N/A	6,140	News Coverage Positive News
RVMD Revolution Medicines	2.524 of 5 stars	$212.00 +4.1%	$161.79 -23.7%	+466.0%	$43.66B	$11.58M	N/A	250	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INSM) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insmed (INSM) Competitors

INSM vs. REGN, ARGX, NTRA, RVMD, and BIIB

How does Insmed compare to Regeneron Pharmaceuticals?

Summary

How does Insmed compare to argenex?

Summary

How does Insmed compare to Natera?

Summary

How does Insmed compare to Revolution Medicines?

Summary

How does Insmed compare to Biogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insmed (INSM) Competitors

INSM vs. REGN, ARGX, NTRA, RVMD, and BIIB

How does Insmed compare to Regeneron Pharmaceuticals?

Which has more risk & volatility, INSM or REGN?

Does the media favor INSM or REGN?

Which has better valuation & earnings, INSM or REGN?

Is INSM or REGN more profitable?

Do analysts recommend INSM or REGN?

Do institutionals and insiders believe in INSM or REGN?

Summary

How does Insmed compare to argenex?

Does the media refer more to INSM or ARGX?

Do analysts recommend INSM or ARGX?

Do institutionals & insiders hold more shares of INSM or ARGX?

Which has more risk and volatility, INSM or ARGX?

Is INSM or ARGX more profitable?

Which has better earnings and valuation, INSM or ARGX?

Summary

How does Insmed compare to Natera?

Is INSM or NTRA more profitable?

Which has more risk and volatility, INSM or NTRA?

Do insiders and institutionals hold more shares of INSM or NTRA?

Which has stronger valuation and earnings, INSM or NTRA?

Do analysts recommend INSM or NTRA?

Does the media prefer INSM or NTRA?

Summary

How does Insmed compare to Revolution Medicines?

Do institutionals and insiders believe in INSM or RVMD?

Is INSM or RVMD more profitable?

Which has stronger earnings and valuation, INSM or RVMD?

Does the media refer more to INSM or RVMD?

Which has more risk & volatility, INSM or RVMD?

Do analysts recommend INSM or RVMD?

Summary

How does Insmed compare to Biogen?

Is INSM or BIIB more profitable?

Do analysts rate INSM or BIIB?

Does the media refer more to INSM or BIIB?

Do insiders & institutionals hold more shares of INSM or BIIB?

Which has better earnings and valuation, INSM or BIIB?

Which has more volatility & risk, INSM or BIIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INSM vs. The Competition

Insmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools